Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision
MONTREAL, November 10, 2015 – Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced today that it received notice of a Decision to Grant on an important composition of matter patent from the Japanese Patent Office. This decision covers Application No. 2012-193673, entitled “Tdf-related compounds and analogs thereof.” This patent provides coverage for Thrasos’ lead product THR-184, currently in Phase 2 clinical testing for the prevention of acute kidney injury (AKI) in patients undergoing cardiac surgery. The Company’s 452 patient Phase 2 trial has completed enrollment and data is expected in early 2016.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.